318 related articles for article (PubMed ID: 29155210)
1. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
2. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
3. 5alpha-Androstane-3alpha,17beta-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation.
Zimmerman RA; Dozmorov I; Nunlist EH; Tang Y; Li X; Cowan R; Centola M; Frank MB; Culkin DJ; Lin HK
Prostate Cancer Prostatic Dis; 2004; 7(4):364-74. PubMed ID: 15452555
[TBL] [Abstract][Full Text] [Related]
4. Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation.
Nunlist EH; Dozmorov I; Tang Y; Cowan R; Centola M; Lin HK
J Steroid Biochem Mol Biol; 2004 Jul; 91(3):157-70. PubMed ID: 15276623
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
6. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
8. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
[TBL] [Abstract][Full Text] [Related]
9. Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells.
Rizner TL; Lin HK; Penning TM
Chem Biol Interact; 2003 Feb; 143-144():401-9. PubMed ID: 12604227
[TBL] [Abstract][Full Text] [Related]
10. Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells - Identifying inhibitors of non-classical pathways producing the most potent androgen.
Boutin S; Roy J; Maltais R; Poirier D
Bioorg Med Chem Lett; 2020 Jan; 30(2):126783. PubMed ID: 31753699
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
12. A neuroactive steroid 5alpha-androstane-3alpha,17beta-diol regulates androgen receptor level in astrocytes.
Agapova OA; Malone PE; Hernandez MR
J Neurochem; 2006 Jul; 98(2):355-63. PubMed ID: 16638015
[TBL] [Abstract][Full Text] [Related]
13. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
15. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
16. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
17. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
18. Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease.
Bauman DR; Steckelbroeck S; Williams MV; Peehl DM; Penning TM
Mol Endocrinol; 2006 Feb; 20(2):444-58. PubMed ID: 16179381
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-androstane-3alpha,17beta-diol selectively activates the canonical PI3K/AKT pathway: a bioinformatics-based evidence for androgen-activated cytoplasmic signaling.
Dozmorov MG; Yang Q; Matwalli A; Hurst RE; Culkin DJ; Kropp BP; Lin HK
Genomic Med; 2007; 1(3-4):139-46. PubMed ID: 18923939
[TBL] [Abstract][Full Text] [Related]
20. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]